FREMONT, Calif., Nov. 10, 2020 /PRNewswire/ -- Ardelyx, Inc.
(Nasdaq: ARDX), a biopharmaceutical company focused on developing
innovative first-in-class medicines to improve treatment for people
with kidney and cardiovascular diseases, today announced that
Mike Raab, president and chief
executive officer of Ardelyx, will participate in a fireside chat
at the Jefferies Virtual London Healthcare Conference on
Tuesday, November 17, 2020 at
1:10 p.m. ET.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor
section of the Ardelyx website at
https://ir.ardelyx.com/events-and-presentations. A replay of the
webcast will be available on the Ardelyx website for 60 days
following the presentation.
About Ardelyx, Inc.
Ardelyx is focused on developing
innovative first-in-class medicines to enhance the lives of
patients with kidney and cardiovascular diseases. Ardelyx is
advancing tenapanor, a novel product candidate to control serum
phosphorus in adult patients with CKD on dialysis, for which the
company's NDA is currently under review by the FDA, with a PDUFA
goal date of April 29, 2021. Ardelyx
is also advancing RDX013, a potassium secretagogue program, for the
potential treatment of high potassium, or hyperkalemia, a problem
among certain patients with kidney and/or heart disease. In
addition, Ardelyx received FDA approval of IBSRELA®
(tenapanor) on September 12, 2019.
Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and
commercialization of tenapanor in the respective territories.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-virtual-london-healthcare-conference-301169441.html
SOURCE Ardelyx